Alba, Emilio
Mayo Clinic
Virgen de la Victoria University Hospitals of Málaga, Malago, Spain.
Citations 3
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial
Abdou, Yara , Barlow, William E. , Meric‐Bernstam, Funda , Albain, Kathy S. , Hayes, Daniel F. , Lin, Nancy U. , Perez, Edith , Goldstein, Lori J. , Chia, Stephen , Dhesy‐Thind, Sukhbinder , Rastogi, Priya , Schott, Anne F. , Shak, Steven , Lew, Danika L., Tripathy, Debasish , Meric-Bernstam, Funda , Hayes, Daniel F , Lin, Nancy U , Dhesy-Thind, Sukhbinder , Rastogi, Priya , Alba, Emilio , Delaloge, Suzette , Schott, Anne F , Sharma, Priyanka , Miao, Jieling , Unger, Joseph M , Hortobagyi, Gabriel N , Pusztai, Lajos , Barlow, William E , Abdou, Yara George , Gralow, Julie R. , Alba, Emilio , Sharma, Priyanka , Miao, Jieling , Unger, Joseph M. , Hortobágyi, Gabriel N. , Pusztai, Lajos , Kalinsky, Kevin M.
JNCI: Journal of the National Cancer Institute | December 3, 2024 | Volume: 117 | Issue: 5 | Pages: 889-897
Abstract Background The phase III RxPONDER trial has affected treatment for node-positive (1-3), hormone receptor-positive, HER2-negative breast cancer with a 21-gene recurrence score (RS) less than 26. We investigated how these findings apply to different racial and ethnic groups within the trial. Methods The trial randomly assigned women to endocrine therapy (ET) or to chemotherapy plus ET. The primary clinical outcome was invasive disease-free survival (IDFS), with distant relapse-free survival (DRFS) as a secondary outcome. Multivariable Cox models were used to evaluate the association between race/ethnicity and survival outcomes, adjusting for clinicopathological characteristics, RS, and treatment. Results A total of 4048 women with self-reported race/ethnicity were included: Hispanic (15.1%), non-Hispanic Black (NHB) (6.1%), Native American/Pacific Islander (0.8%), Asian (8.0%), and non-Hispanic White (NHW) (70%). No differences in RS distribution, tumor size, or number of positive nodes were observed by race/ethnicity. Relative to NHWs, IDFS was worse for NHB participants (5-year IDFS 91.6% vs 87.1%, HR = 1.37; 95% CI = 1.03 to 1.81) and better for Asians (91.6% vs 93.9%, HR = 0.64; 95% CI = 0.46 to 0.91). Relative to NHW, DRFS was worse for NHB participants (5-year DRFS 95.8% vs 91.0%, HR = 1.65; 95% CI = 1.17 to 2.32) and better for Asians (95.8% vs 96.7%, HR = 0.59; 95% CI = 0.37 to 0.95). Adjusting for clinical characteristics, particularly body mass index, diminished the effect of race on outcomes. Chemotherapy treatment efficacy did not differ by race/ethnicity. Conclusions NHB women had worse clinical outcomes compared with NHWs in the RxPONDER trial despite similar RS and comparable treatment. Our study emphasizes the persistent racial disparities in breast cancer outcomes while highlighting complex interactions among contributing factors. Trial Registration ClinicalTrials.gov: NCT01272037.
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Kalinsky, Kevin, Barlow, William E., Gralow, Julie R., Meric-Bernstam, Funda, Albain, Kathy S., Hayes, Daniel F., Lin, Nancy U., Perez, Edith A., Goldstein, Lori J., Chia, Stephen K.L., Dhesy-Thind, Sukhbinder, Rastogi, Priya, Alba, Emilio, Delaloge, Suzette, Kelly, Catherine M., Ruiz-Borrego, Manuel, Gil-Gil, Miguel, Arce-Salinas, Claudia H., Brain, Etienne G.C., Lee, Eun-Sook, Pierga, Jean-Yves, Bermejo, Begoña, Ramos-Vazquez, Manuel, Jung, Kyung-Hae, Ferrero, Jean-Marc, Schott, Anne F., Shak, Steven, Sharma, Priyanka, Lew, Danika L., Miao, Jieling, Tripathy, Debasish, Pusztai, Lajos, Alba, Emilio , Tripathy, Debu , Kelly, Catherine M. , Dhesy‐Thind, Sukhbinder , Martin, Miguel , Hortobagyi, Gabriel N , Tripathy, Debasish , Dhesy-Thind, Sukhbinder , Alba, Emilio , Kalinsky, Kevin, Barlow, William E., Gralow, Julie R., Meric-Bernstam, Funda, Albain, Kathy S., Hayes, Daniel F., Lin, Nancy U., Perez, Edith A., Goldstein, Lori J., Chia, Stephen K.L., Rastogi, Priya, Delaloge, Suzette, Kelly, Catherine M., Ruiz-Borrego, Manuel, Gil-Gil, Miguel, Arce-Salinas, Claudia H., Brain, Etienne G.C., Lee, Eun-Sook, Pierga, Jean-Yves, Bermejo, Begoña, Ramos-Vazquez, Manuel, Jung, Kyung-Hae, Ferrero, Jean-Marc, Schott, Anne F., Shak, Steven, Sharma, Priyanka, Lew, Danika L., Miao, Jieling, Pusztai, Lajos
New England Journal of Medicine | December 1, 2021 | Volume: 385 | Issue: 25 | Pages: 2336-2347
Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations
Martín, Miguel , Esteva, Francisco J. , Alba, Emilio , Khandheria, Bijoy K. , Pérez-Isla, Leopoldo, García-Sáenz, José Á. , Márquez, Antonia, Sengupta, Partho P. , Zamorano, José Luis , Isla, Leopoldo Pérez de , García-Sáenz, José A , Martin, Miguel , Alba, Emilio
The Oncologist | January 16, 2009 | Volume: 14 | Issue: 1 | Pages: 1-11
10.1634/theoncologist.2008-0137
Learning Objectives Analyze the clinical trial data for the treatment of breast cancer. Evaluate the risk of cardiotoxicity associated with the use of trastuzumab. Design and conduct a practical approach to managing patients with trastuzumab-associated cardiotoxicity. This article is available for continuing medical education credit at CME.TheOncologist.com.